Adjuvant therapy in non-small cell lung cancer: is targeted therapy joining the standard of care?
Carolina GabayAlessandro RussoLuis E RaezChristian Rolfo CervettoPublished in: Expert review of anticancer therapy (2021)
The results of the first adjuvant clinical trial with TKIs showed increased DFS in patients with early-stage NSCLC. Despite that using osimertinib (Osm) as an adjuvant treatment seems promising, several open questions need to be answered. If Osm reaches a significant advantage in OS, undergoing 3 years of treatment is worthwhile, but if there is not an OS benefit then maybe DFS is not enough. In the meantime, should we treat patients with Osm as adjuvant therapy until the OS data is available? There is not an easy answer, but most of us are in favor of giving Osm a chance until we have definitive data or better options in early-stage NSCLC.
Keyphrases
- early stage
- small cell lung cancer
- clinical trial
- advanced non small cell lung cancer
- healthcare
- electronic health record
- palliative care
- sentinel lymph node
- big data
- randomized controlled trial
- squamous cell carcinoma
- minimally invasive
- open label
- combination therapy
- radiation therapy
- chronic pain
- dna repair
- quality improvement
- replacement therapy
- data analysis
- brain metastases
- health insurance